The industry's most comprehensive source on the generic durg industry in the US.
Coverage includes sections:
- Products / Market - Regulatory - Top company profiles
TOPICS COVERED INCLUDE:
- Impact of the NEW Obama Administration on the Generic Drug Industry - Analysis of recent Patent Litigation effecting the Generic Drug Industry - Medicare and Medicaid pricing policies - Intellectual property status and expirations dates for all branded drug products - Emerging competition in India,China and Eastern Europe - Recent Mergers and Aquistions - Impact of Bio generics
Product & Market Section:
- Five-year market forecast - Opportunity assessment for products losing patent protection 2009–2014 - Top 400 branded and generic products (sales and growth rates) - Patent & exclusivity data for every FDA-approved product - Top 20 therapeutic categories - Total category sales - Share by company within therapeutic category and more
Regulatory Section:
- FDA structure and policies - Administrative actions and trends - Hatch-Waxman trends in case law - Paragraph IV challenges and success rates and more
Company Section:
- Senior Executive contact information - Company strategy & therapeutic focus - Formulation capabilities - Drug Master Files (DMF’s) - Ownership (public vs. private) - Financial data (public companies) and more
Publication Highlights:
- New FDA and FTC regulations - Analysis of recent court decisions on authorized generics, recent out-of-court settlements and Paragraph IV challenges - Biogeneric developments in Europe and US - Analysis of emerging providers in India, China and Eastern Europe - Up-to-date patent and exclusivity information
